Linden Thomas Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Linden Thomas Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$728K	Sell	12,137 -140	-1%	-$8.82K	0.06%	376
2026 Q2	$702K	Sell	12,277 -26	-0.2%	-$1.42K	0.06%	383
2026 Q1	$695K	Buy	+12,303	New	+$717K	0.07%	358
2024 Q2	–	Sell	-17,900	Closed	-$1.56M	–	453
2024 Q1	$1.56M	Buy	17,900 +17	+0.1%	+$1.52K	0.25%	151
2023 Q4	$1.72M	Sell	17,883 -166	-0.9%	-$14.7K	0.32%	105
2023 Q3	$1.6M	Sell	18,049 -542	-3%	-$48.2K	0.36%	84
2023 Q2	$1.61M	Buy	18,591 +80	+0.4%	+$7.53K	0.36%	87
2023 Q1	$1.8M	Buy	18,511 +459	+3%	+$47.6K	0.45%	58
2022 Q4	$1.87M	Buy	+18,052	New	+$1.69M	0.53%	40

Other funds holding BMRN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

ARGA Investment Management Stamford, Connecticut $3.94B AUM 28.9% 1-Year Est. Return

Edmond de Rothschild Holding Chambesy, Switzerland $8.18B AUM 23.81% 1-Year Est. Return

Linden Thomas Advisory Services's BMRN Position: Q3 2026 in Review

Linden Thomas Advisory Services reduced its BioMarin Pharmaceuticals (BMRN) stake by 1.1% in Q3 2026, selling an estimated $8.82K and leaving 12,137 shares worth $728K. The position accounts for 0.06% of the portfolio, ranked #376.

Linden Thomas Advisory Services first reported a position in BMRN in Q4 2022 and has held it in 9 quarters since. The position peaked at $1.87M in Q4 2022. 308 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Linden Thomas Advisory Services held 12,137 shares of BioMarin Pharmaceuticals worth $728K as of Q3 2026.
Linden Thomas Advisory Services sold 140 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $8.82K.
BioMarin Pharmaceuticals made up 0.06% of Linden Thomas Advisory Services's portfolio in Q3 2026, its #376 holding.
Linden Thomas Advisory Services first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
Linden Thomas Advisory Services's BioMarin Pharmaceuticals position peaked at $1.87M in Q4 2022.
308 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q3 2026, filed 19 Oct 2026.